[Current approaches to the diagnosis and treatment of postmenopausal osteoporosis].
Postmenopausal osteoporosis (OP) is a disease afflicting every three women above 50 years of age. The sociomedical significance of OP is determined by the development of fracture in minimal injuries resulting in disability and, occasionally, death. The review presents a new management strategy described in the European and Russian guidelines. Particular emphasis is laid on the early identification and treatment of patients at high risk for fractures. The current requirements for drugs used to treat OP are described, by using as an example strontium ranelate, one of the first-line agents for the treatment of postmenopausal OP.
Baranova
I A
IA
D000367:Age Factors; D000368:Aged; D000465:Algorithms; D015992:Body Mass Index; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate